Background & Aims
Methods
Results
Conclusions
Abbreviations:
HCV (hepatitis C), NHS (National Health Service), NICE (National Institute for Health and Care Excellence (formally National Institute for Health and Clinical Excellence)), HPAI (Hospital Pharmacy Audit Index), ESLD (end-stage liver disease), HCC (hepatocellular carcinoma), HES (Hospital episode statistics), SVR (sustained viral response), DAA (direct acting antiviral), QALY (quality adjusted life year), CrI (credible interval)Keywords
Introduction
Materials and methods
Data on drugs used for treatment of hepatitis C
(i) Ex-factory sales to NHS hospitals
(ii) Pharmex – National usage by primary buying groups
Department of Health. Commercial medicines unit. http://cmu.dh.gov.uk/; 2014 [accessed 28.2.14].
(iii) IMS HEALTH Hospital Pharmacy Audit Index (HPAI)
Back-calculation model
Burden projection

Treatment scenarios
![]() |
- Kwo P.Y.
- Lawitz E.J.
- McCone J.
- Schiff E.R.
- Vierling J.M.
- Pound D.
- et al.
American Association for the Study of Liver Diseases and Infectious Diseases Society for America. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report-view; 2014 [accessed 20.2.14].
where Ci and Ei are the cost and number of events respectively under scenario i, and scenario 2 is being compared to the base case scenario 1. Results are presented in UK pounds sterling. Healthcare costs were adjusted according to the hospital community health services pay and prices index [
American Association for the Study of Liver Diseases and Infectious Diseases Society for America. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report-view; 2014 [accessed 20.2.14].
Results
Trends in treatment levels

Future burden of HCV and impact of treatment


Cost of treatment
Sensitivity analyses
Discussion
Principal findings
Strengths and weaknesses
Implications for clinicians and policymakers
Hezode C, Dorival C, Zoulim F, Poynard T, Mathurin P, Pol S et al. Safety of Telaprevir or Boceprevir in combination with Peginterferon alfa/Ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC). In: 47th Meeting of the European Association for the Study of the Liver (EASL), Barcelona; 2012.
New York Times; F.D.A. Approves pill to treat hepatitis C. http://www.nytimes.com/2013/12/07/business/fda-approves-pill-to-treat-hepatitis-c.html; 2014 [accessed 19.1.14].
Final remarks
Financial support
Conflict of interest
Acknowledgments
Supplementary data
- Supplementary data
References
- Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis.Eur J Public Health. 2012; 22: 187-192
- The burden of hepatitis C in England.J Viral Hepat. 2007; 14: 570-576
- Harris H.E. Ramsay M.E. Hepatitis C in the UK 2012 Report. Health Protection Agency, Colindale, London2012
National Institute for Health and Clinical Excellence. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C 75; 2004. Technology Appraisal.
- Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C 106.NICE technology appraisal guidance, 2006
- Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C 200.NICE technology appraisal guidance, 2010
- Boceprevir for the treatment of genotype 1 chronic hepatitis C 253.NICE technology appraisal guidance, 2012
- Telaprevir for the treatment of genotype 1 chronic hepatitis C 252.NICE technology appraisal guidance, 2012
- Variation in hepatitis C services may lead to inequity of health-care provision: a survey of the organisation and delivery of services in the United Kingdom.BMC Public Health. 2006; 6: 3
- Healthy lives, healthy people: improving outcomes and supporting transparency.Department of Health, London2012
- The NHS outcomes framework 2013–14.Department of Health, London2012
- Health Protection Agency Harris H.E. Ramsay M.E. Hepatitis C in the UK 2012 report. Health Protection Agency, Colindale, London2012
- Hepatitis C action plan for England.Department of Health, London2004
Department of Health. Commercial medicines unit. http://cmu.dh.gov.uk/; 2014 [accessed 28.2.14].
- Harris H.E. Ramsay M.E. Hepatitis C in the UK 2009. Health Protection Agency Centre for Infections, London2009
- Minimum size of the acquired immunodeficiency syndrome (AIDS) epidemic in the United States.Lancet. 1986; 2: 1320-1322
King R, Bird SM, Hay G, Hutchinson SJ. Estimating Prevalence of Injecting Drug Users and Associated Death Rates in England Using Regional Data and Incorporating Prior Information; 2012.
- Capture–recapture and anchored prevalence estimation of injecting drug users in England: national and regional estimates.Stat Methods Med Res. 2009; 18: 323-339
- Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.BMC Infect Dis. 2006; 6: 93
- Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management.J Viral Hepat. 2008; 15: 271-278
- A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus.Clin Gastroenterol Hepatol. 2010; 8: 280-288
- Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States.Liver Transpl. 2007; 13: 719-724
- Predicted effects of treatment for HCV infection vary among European countries.Gastroenterology. 2012; 143: 974-985
- Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.Lancet. 2010; 376: 705-716
- Boceprevir for untreated chronic HCV genotype 1 infection.N Engl J Med. 2011; 364: 1195-1206
- Telaprevir for previously untreated chronic hepatitis C virus infection.N Engl J Med. 2011; 364: 2405-2416
- Current prospects for interferon-free treatment of hepatitis C in 2012.J Gastroenterol Hepatol. 2013; 28: 1440-1746
Lok AS, Gardiner DF, Hezode C. Sustained virologic response in chronic HCV genotype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a/ribavirin (PEG/RBV), 12 Nov 9; Boston; 2012.
American Association for the Study of Liver Diseases and Infectious Diseases Society for America. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report-view; 2014 [accessed 20.2.14].
- The efficacy and safety of the interferon-free combination of BI201335 and BI207127 in genotype 1 HCV patients with cirrhosis – interim analysis from SOUND-C2.The International Liver Congress 2012, Barcelona, Spain2012
- Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.Health Technol Assess. 2007; 11 (iii): 1-205
Department of Health. Hospital and Community Health Services (HCHS) pay and price inflation; 2010.
- Guide to the methods of technology appraisal.NICE public health guidance, 2013
- WinBUGS Version 1.4 User Manual.MRC Biostatistics Unit, Cambridge2003
- New therapy explains the fall in AIDS incidence with a substantial rise in number of persons on treatment expected.AIDS. 1999; 13: 103-108
- Costing template and costing report. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B 96.NICE technology appraisal, 2006
- State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3.Med Decis Making. 2012; 32: 690-700
- Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.Hepatology. 2008; 48: 418-431
- Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France.J Hepatol. 2008; 49: 175-183
- Empirically calibrated model of hepatitis C virus infection in the United States.Am J Epidemiol. 2002; 156: 761-773
- Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment.J Clin Epidemiol. 2006; 59: 144-152
- Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations.Hepatology. 2012; 55: 49-57
- Hepatitis B and C: ways to promote and offer testing to people at increased risk of infection 43.NICE public health guidance, 2012
Hezode C, Dorival C, Zoulim F, Poynard T, Mathurin P, Pol S et al. Safety of Telaprevir or Boceprevir in combination with Peginterferon alfa/Ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC). In: 47th Meeting of the European Association for the Study of the Liver (EASL), Barcelona; 2012.
- New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.Ann Intern Med. 2012; 156: 279-290
New York Times; F.D.A. Approves pill to treat hepatitis C. http://www.nytimes.com/2013/12/07/business/fda-approves-pill-to-treat-hepatitis-c.html; 2014 [accessed 19.1.14].
Article info
Publication history
Identification
Copyright
User license
Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
Permitted
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
Not Permitted
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy